A double blind, within subject comparison of spontaneous opioid withdrawal from buprenorphine versus morphines

Journal of Pharmacology and Experimental Therapeutics

Volumn 348, Issue 2, 2014, Pages 217-226

  Tompkins, D Andrew ^a   Smith, Michael T ^a   Mintzer, Miriam Z ^a   Campbell, Claudia M ^b   Strain, Eric C ^c  

^a JOHNS HOPKINS BAYVIEW MEDICAL CENTER   (United States)

^b Department of Psychiatry and Behavioral Sciences   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUPRENORPHINE; MORPHINE; OPIATE; PLACEBO;

ADULT; ARTICLE; BEDTIME DOSAGE; BREATHING RATE; CLINICAL OPIATE WITHDRAWAL SCALE; COGNITION; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG POTENCY; DRUG WITHDRAWAL; HEART RATE; HUMAN; MALE; MORNING DOSAGE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; OPIATE ADDICTION; OPIOID WITHDRAWAL SYNDROME; PAIN ASSESSMENT; PRIORITY JOURNAL; PSYCHOMOTOR ACTIVITY; PUPIL REFLEX; SUBJECTIVE OPIATE WITHDRAWAL SCALE; SYSTOLIC BLOOD PRESSURE; TASK PERFORMANCE; VISUAL ANALOG SCALE; WITHDRAWAL SYNDROME;

EID: 84893143304     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.113.209478     Document Type: Article

References (60)

1. Amass L, Kamien JB, and Mikulich SK (2001) Thrice-weekly supervised dosing with the combination buprenorphine-naloxone tablet is preferred to daily supervised dosing by opioid-dependent humans. Drug Alcohol Depend 61:173-181.
2. American Psychiatric Association (2000) Diagnostic and Statistical Manual of Mental Disorders, American Psychiatric Association, Washington, D.C.
3. Assadi SM, Hafezi M, Mokri A, Razzaghi EM, and Ghaeli P (2004) Opioid detoxification using high doses of buprenorphine in 24 hours: a randomized, double blind, controlled clinical trial. J Subst Abuse Treat 27:75-82.
4. Bastien CH, Vallières A, and Morin CM (2001) Validation of the Insomnia Severity Index as an outcome measure for insomnia research. Sleep Med 2:297-307.
5. Bloms-Funke P, Gillen C, Schuettler AJ, and Wnendt S (2000) Agonistic effects of the opioid buprenorphine on the nociceptin/OFQ receptor. Peptides 21:1141-1146.
6. Bullingham RE, McQuay HJ, Moore A, and Bennett MR (1980) Buprenorphine kinetics. Clin Pharmacol Ther 28:667-672.
7. Buysse DJ, Reynolds CF, 3rd, Monk TH, Berman SR, and Kupfer DJ (1989) The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res 28:193-213.
8. Center for Substance Abuse Treatment (2004) Clinical guidelines for the use of buprenorphine in the treatment of opioid addiction. Treatment Improvement Protocol (TIP) Series 40. Substance Abuse and Mental Health Services Administration, Rockville, MD.
9. Christie MJ (2008) Cellular neuroadaptations to chronic opioids: tolerance, withdrawal and addiction. Br J Pharmacol 154:384-396.
10. Compton P, Ling W, Moody D, and Chiang N (2006) Pharmacokinetics, bioavailability and opioid effects of liquid versus tablet buprenorphine. Drug Alcohol Depend 82:25-31.
11. Correia CJ, Walsh SL, Bigelow GE, and Strain EC (2006) Effects associated with double-blind omission of buprenorphine/naloxone over a 98-h period. Psychopharmacology (Berl) 189:297-306.
12. Cowan A, Lewis JW, and Macfarlane IR (1977) Agonist and antagonist properties of buprenorphine, a new antinociceptive agent. Br J Pharmacol 60:537-545.
13. Dum J, Bläsig J, and Herz A (1981) Buprenorphrine: demonstration of physical dependence liability. Eur J Pharmacol 70:293-300.
14. Dum JE and Herz A (1981) In vivo receptor binding of the opiate partial agonist, buprenorphine, correlated with its agonistic and antagonistic actions. Br J Pharmacol 74:627-633.
15. Eissenberg T, Greenwald MK, Johnson RE, Liebson IA, Bigelow GE, and Stitzer ML (1996) Buprenorphine's physical dependence potential: antagonist-precipitated withdrawal in humans. J Pharmacol Exp Ther 276:449-459.
16. Elkader A and Sproule B (2005) Buprenorphine: clinical pharmacokinetics in the treatment of opioid dependence. Clin Pharmacokinet 44:661-680.
17. First MB, Spitzer RL, Gibbon M, and Williams JBW (2002) Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition. (SCIDI/ P), Biometrics Research, New York State Psychiatric Institute, New York.
18. Fudala PJ, Jaffe JH, Dax EM, and Johnson RE (1990) Use of buprenorphine in the treatment of opioid addiction. II. Physiologic and behavioral effects of daily and alternate-day administration and abrupt withdrawal. Clin Pharmacol Ther 47: 525-534.
19. Greenwald M, Johanson CE, Bueller J, Chang Y, Moody DE, Kilbourn M, Koeppe R, and Zubieta JK (2007) Buprenorphine duration of action: mu-opioid receptor availability and pharmacokinetic and behavioral indices. Biol Psychiatry 61: 101-110.
20. Greenwald MK, Johanson CE, Moody DE, Woods JH, Kilbourn MR, Koeppe RA, Schuster CR, and Zubieta JK (2003) Effects of buprenorphine maintenance dose on mu-opioid receptor availability, plasma concentrations, and antagonist blockade in heroin-dependent volunteers. Neuropsychopharmacology 28:2000-2009.
21. Griffiths RR, Bigelow GE, and Liebson I (1983) Differential effects of diazepam and pentobarbital on mood and behavior. Arch Gen Psychiatry 40:865-873.
22. Handelsman L, Cochrane KJ, Aronson MJ, Ness R, Rubinstein KJ, and Kanof PD (1987) Two new rating scales for opiate withdrawal. Am J Drug Alcohol Abuse 13: 293-308.
23. Himmelsbach CK (1941) The morphine abstinence syndrome, its nature and treatment. Ann Intern Med 15:829-839.
24. Jasinski DR (1977) Assessment of the abuse potentiality of morphine-like drugs (methods used in man), in Drug Addiction I (Martin WR, ed) pp 197-258 Springer-Verlag, Berlin.
25. Jasinski DR, Pevnick JS, and Griffith JD (1978) Human pharmacology and abuse potential of the analgesic buprenorphine: a potential agent for treating narcotic addiction. Arch Gen Psychiatry 35:501-516.
26. Johnson RE, Chutuape MA, Strain EC, Walsh SL, Stitzer ML, and Bigelow GE (2000) A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence. N Engl J Med 343:1290-1297.
27. Johnson RE, Eissenberg T, Stitzer ML, Strain EC, Liebson IA, and Bigelow GE (1995) Buprenorphine treatment of opioid dependence: clinical trial of daily versus alternate-day dosing. Drug Alcohol Depend 40:27-35.
28. Kirk T, Roache JD, and Griffiths RR (1990) Dose-response evaluation of the amnestic effects of triazolam and pentobarbital in normal subjects. J Clin Psychopharmacol 10:160-167.
29. Kosten TR (1990) Current pharmacotherapies for opioid dependence. Psychopharmacol Bull 26:69-74.
30. Kuhlman JJ Jr, Lalani S, Magluilo J Jr, Levine B, Darwin WD, Johnson RE, and Cone EJ (1996) Human pharmacokinetics of intravenous, sublingual, and buccal buprenorphine. J Anal Toxicol 20:369-378.
31. Kuhlman JJ Jr, Levine B, Johnson RE, Fudala PJ, and Cone EJ (1998) Relationship of plasma buprenorphine and norbuprenorphine to withdrawal symptoms during dose induction, maintenance and withdrawal from sublingual buprenorphine. Addiction 93:549-559.
32. Lee KO, Akil H, Woods JH, and Traynor JR (1999) Differential binding properties of oripavines at cloned m-and d-opioid receptors. Eur J Pharmacol 378:323-330.
33. Lewis JW and Husbands SM (2004) The orvinols and related opioids-high affinity ligands with diverse efficacy profiles. Curr Pharm Des 10:717-732.
34. Lutfy K, Eitan S, Bryant CD, Yang YC, Saliminejad N, Walwyn W, Kieffer BL, Takeshima H, Carroll FI, and Maidment NT,, et al. (2003) Buprenorphine-induced antinociception is mediated by mu-opioid receptors and compromised by concomitant activation of opioid receptor-like receptors. J Neurosci 23:10331-10337.
35. Martin WR, Eades CG, Thompson JA, Huppler RE, and Gilbert PE (1976) The effects of morphine-and nalorphine-like drugs in the nondependent and morphinedependent chronic spinal dog. J Pharmacol Exp Ther 197:517-532.
36. Mattick RP, Kimber J, Breen C, and Davoli M (2008) Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev (2):CD002207.pub3.
37. McLeod DR, Griffiths RR, Bigelow GE, and Yingling J (1982) An automated version of the digit symbol substitution test (DSST). Behav Res Meth Instrum 14:463-466.
38. McNair DM, Lorr M, and Droppleman L (1971) EITS Manual for the Profile of Mood States, Educational and Industrial Testing Service, San Diego.
39. Mello NK and Mendelson JH (1980) Buprenorphine suppresses heroin use by heroin addicts. Science 207:657-659.
40. Mintzer MZ, Frey JM, Yingling JE, and Griffiths RR (1997) Triazolam and zolpidem: a comparison of their psychomotor, cognitive, and subjective effects in healthy volunteers. Behav Pharmacol 8:561-574.
41. Mintzer MZ and Griffiths RR (2003) Triazolam-amphetamine interaction: dissociation of effects on memory versus arousal. J Psychopharmacol 17:17-29.
42. Moody DE, Fang WB, Morrison J, and McCance-Katz E (2011) Gender differences in pharmacokinetics of maintenance dosed buprenorphine. Drug Alcohol Depend 118: 479-483.
43. Negus SS, Bidlack JM, Mello NK, Furness MS, Rice KC, and Brandt MR (2002) Delta opioid antagonist effects of buprenorphine in rhesus monkeys. Behav Pharmacol 13:557-570.
44. Nigam AK, Srivastava RP, Saxena S, Chavan BS, and Sundaram KR (1994) Naloxone-induced withdrawal in patients with buprenorphine dependence. Addiction 89:317-320.
45. Pickworth WB, Lee H, and Fudala PJ (1990) Buprenorphine-induced pupillary effects in human volunteers. Life Sci 47:1269-1277.
46. Preston KL and Bigelow GE (1993) Differential naltrexone antagonism of hydromorphone and pentazocine effects in human volunteers. J Pharmacol Exp Ther 264:813-823.
47. Reitan RM (1958) The validity of the trail-making test as an indicator of organic brain damage. Percept Mot Skills 8:271-276.
48. Schuh KJ and Johanson CE (1999) Pharmacokinetic comparison of the buprenorphine sublingual liquid and tablet. Drug Alcohol Depend 56:55-60.
49. Stoller KB, Bigelow GE, Walsh SL, and Strain EC (2001) Effects of buprenorphine/ naloxone in opioid-dependent humans. Psychopharmacology (Berl) 154:230-242.
50. Strain EC, Moody DE, Stoller KB, Walsh SL, and Bigelow GE (2004) Relative bioavailability of different buprenorphine formulations under chronic dosing conditions. Drug Alcohol Depend 74:37-43.
51. Strain EC, Preston KL, Liebson IA, and Bigelow GE (1995) Buprenorphine effects in methadone-maintained volunteers: effects at two hours after methadone. J Pharmacol Exp Ther 272:628-638.
52. Strain EC, Stoller K, Walsh SL, and Bigelow GE (2000) Effects of buprenorphine versus buprenorphine/naloxone tablets in non-dependent opioid abusers. Psychopharmacology (Berl) 148:374-383.
53. Tompkins DA, Bigelow GE, Harrison JA, Johnson RE, Fudala PJ, and Strain EC (2009) Concurrent validation of the Clinical Opiate Withdrawal Scale (COWS) and single-item indices against the Clinical Institute Narcotic Assessment (CINA) opioid withdrawal instrument. Drug Alcohol Depend 105:154-159.
54. Walker EA, Zernig G, and Woods JH (1995) Buprenorphine antagonism of mu opioids in the rhesus monkey tail-withdrawal procedure. J Pharmacol Exp Ther 273:1345-1352.
55. Wesson DR and Ling W (2003) The clinical opiate withdrawal scale (COWS). J Psychoactive Drugs 35:253-259.
56. Westermeyer J and McCance-Katz EF (2012) Course and treatment of buprenorphine/naloxone withdrawal: an analysis of case reports. Am J Addict 21: 401-403.
57. Wolff RF, Aune D, Truyers C, Hernandez AV, Misso K, Riemsma R, and Kleijnen J (2012) Systematic review of efficacy and safety of buprenorphine versus fentanyl or morphine in patients with chronic moderate to severe pain. Curr Med Res Opin 28: 833-845.
58. Yamamoto T, Shono K, and Tanabe S (2006) Buprenorphine activates mu and opioid receptor like-1 receptors simultaneously, but the analgesic effect is mainly mediated by mu receptor activation in the rat formalin test. J Pharmacol Exp Ther 318: 206-213.
59. Ziedonis DM, Amass L, Steinberg M, Woody G, Krejci J, Annon JJ, Cohen AJ, Waite-O'Brien N, Stine SM, and McCarty D, et al. (2009) Predictors of outcome for shortterm medically supervised opioid withdrawal during a randomized, multicenter trial of buprenorphine-naloxone and clonidine in the NIDA clinical trials network drug and alcohol dependence. Drug Alcohol Depend 99:28-36.
60. Zubieta J, Greenwald MK, Lombardi U, Woods JH, Kilbourn MR, Jewett DM, Koeppe RA, Schuster CR, and Johanson CE (2000) Buprenorphine-induced changes in mu-opioid receptor availability in male heroin-dependent volunteers: a preliminary study. Neuropsychopharmacology 23:326-334.